Anadenanthera peregrina

Anadenanthera peregrina is an Amazonian leguminous tree whose bark extract (RAG) contains bioactive compounds that modulate intestinal ion transport. Research demonstrates its potential for reducing diarrhea through enhanced Na+/K+-ATPase activity and inhibition of chloride secretion.

Origin & History

Anadenanthera peregrina is a leguminous tree native to South American savannas, particularly Brazil, Argentina, and Paraguay, whose seeds contain psychoactive tryptamines and have been used traditionally for ritual snuffs. The closely related A. colubrina yields red angico gum (RAG), a biopolymer extracted from trunk exudate with a molar mass of 1.89 × 10^5 g/mol, though most available research focuses on this related species rather than A. peregrina specifically.

Historical & Cultural Context

Anadenanthera peregrina and A. colubrina seeds have been used for millennia by indigenous South American groups including the Piaroa and Cuiva to prepare psychoactive yopo snuff for ritual purposes. Contemporary use persists among pre-Hispanic-descended peoples, while A. colubrina bark and gum feature in Brazilian traditional medicine for treating diarrhea and inflammation.

Health Benefits

• May reduce diarrhea symptoms - mouse studies show RAG reduced castor oil-, cholera toxin-, and E. coli-induced diarrhea by up to 51.61% (preclinical evidence only)
• Potentially supports intestinal health - RAG enhanced Na+/K+-ATPase activity and inhibited chloride secretion in mouse models (PMID: 31963683)
• May modulate immune response - ethanolic bark extract improved clinical scores in experimental autoimmune encephalomyelitis mice (preclinical evidence)
• Shows antiproliferative effects - in vitro studies noted effects on HaCaT keratinocytes and NCI-H460 lung cells (preliminary evidence)
• Traditional use for inflammation - Brazilian semi-arid communities use bark and gum medicinally, though human studies are lacking

How It Works

RAG extract from Anadenanthera peregrina enhances Na+/K+-ATPase enzyme activity in intestinal epithelial cells, promoting sodium reabsorption. The extract simultaneously inhibits chloride secretion, reducing fluid loss into the intestinal lumen. These dual mechanisms help restore normal electrolyte balance and reduce diarrheal fluid secretion.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for Anadenanthera peregrina or A. colubrina. All available evidence comes from preclinical mouse models, including studies on RAG's antidiarrheal effects (PMID: 31963683) and ethanolic bark extract's immunomodulatory properties in EAE models, with typical group sizes of 6-7 animals showing statistical significance (p<0.05) versus controls.

Clinical Summary

Current evidence is limited to preclinical mouse studies examining RAG extract effects on induced diarrhea models. Research showed 51.61% reduction in castor oil-induced diarrhea, with additional protective effects against cholera toxin and E. coli-induced intestinal fluid secretion. No human clinical trials have been conducted to date. The evidence strength remains preliminary, requiring human studies to establish therapeutic potential and optimal dosing protocols.

Nutritional Profile

Anadenanthera peregrina (yopo/cohoba) nutritional composition is not characterized as a food ingredient; it is primarily studied as a medicinal/ethnobotanical plant. Bioactive compounds are the primary focus of available data. Key documented bioactive compounds include: tryptamine alkaloids — bufotenine (5-hydroxy-N,N-dimethyltryptamine) as the dominant alkaloid, typically 0.06–2.94% dry weight in seeds, alongside N,N-dimethyltryptamine (DMT) and 5-MeO-DMT at trace to minor concentrations; beta-carboline alkaloids including harmine and harmaline detected in bark and seed fractions. Bark contains condensed tannins (proanthocyanidins) and the bioactive fraction identified as RAG (a polysaccharide-rich fraction) which demonstrated functional activity in preclinical studies — exact concentration in crude bark not precisely quantified in available literature. Phenolic compounds including flavonoids (quercetin and kaempferol glycosides) and gallic acid derivatives have been identified in bark extracts. Saponins are reported in seed fractions. Fiber content: seeds contain structural polysaccharides (arabinogalactans contributing to the RAG fraction); precise dietary fiber quantification not established in peer-reviewed sources. Protein and macronutrient breakdown (carbohydrates, fats, calories) have not been formally characterized in nutritional databases, as the plant is not consumed as a conventional food. Mineral content is unreported in available literature. Bioavailability note: alkaloid absorption is route- and matrix-dependent; bufotenine shows limited oral bioavailability due to MAO metabolism; tannins may reduce absorption of co-administered nutrients.

Preparation & Dosage

No clinically studied human dosages exist. Mouse studies used RAG pre-treatment (compared to loperamide/gentamicin at 8 mg/kg) and ethanolic bark extract via oral gavage, but exact doses were not specified. No standardized forms or human dosage recommendations are available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Probiotics, Psyllium husk, Slippery elm, Marshmallow root, L-glutamine

Safety & Interactions

No human safety data exists for Anadenanthera peregrina extract supplementation. The plant contains psychoactive alkaloids including bufotenin and 5-MeO-DMT, which could cause adverse neurological effects. Potential interactions with psychiatric medications, MAO inhibitors, and serotonergic drugs are theoretically possible. Pregnant and breastfeeding women should avoid use due to unknown safety profile and alkaloid content.